Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.5.3437190
L. Fernández Bertolín
{"title":"Pipeline on the Move - May 2022","authors":"L. Fernández Bertolín","doi":"10.1358/dof.2022.47.5.3437190","DOIUrl":"https://doi.org/10.1358/dof.2022.47.5.3437190","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.8.3455365
X. Riu Martinez, R. Bandari, A. Lalitha
The American Society of Clinical Oncology (ASCO) is the largest oncology organization in the world, comprising nearly 45,000 oncology professionals. This 58th ASCO annual meeting was held from June 3 to 7 in Chicago, where plenary, oral, educational and poster sessions were presented in person and/or virtually due to the COVID-19 pandemic. All sessions discussed different topics related to oncology including data from clinical studies for the treatment of various cancers, updates in cutting-edge cancer research or the current existing treatments and future considerations, and new drugs or treatment options. This congress brought together cancer experts from all over the world operating under the ASCO principle of "Knowledge conquers cancer" to try and reach its main goal of preventing or curing cancer and improving the quality of life of cancer patients.
{"title":"American Society of Clinical Oncology (ASCO) - 58th Annual Meeting. Chicago/Virtual - June 3-7, 2022","authors":"X. Riu Martinez, R. Bandari, A. Lalitha","doi":"10.1358/dof.2022.47.8.3455365","DOIUrl":"https://doi.org/10.1358/dof.2022.47.8.3455365","url":null,"abstract":"The American Society of Clinical Oncology (ASCO) is the largest oncology organization in the world, comprising nearly 45,000 oncology professionals. This 58th ASCO annual meeting was held from June 3 to 7 in Chicago, where plenary, oral, educational and poster sessions were presented in person and/or virtually due to the COVID-19 pandemic. All sessions discussed different topics related to oncology including data from clinical studies for the treatment of various cancers, updates in cutting-edge cancer research or the current existing treatments and future considerations, and new drugs or treatment options. This congress brought together cancer experts from all over the world operating under the ASCO principle of \"Knowledge conquers cancer\" to try and reach its main goal of preventing or curing cancer and improving the quality of life of cancer patients.","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66445268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.10.3453463
E. Gaskill, S. Price
{"title":"Glofitamab. Anti-CD20 T-cell-engaging bispecific antibody, Treatment of non-Hodgkin lymphoma","authors":"E. Gaskill, S. Price","doi":"10.1358/dof.2022.47.10.3453463","DOIUrl":"https://doi.org/10.1358/dof.2022.47.10.3453463","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66440669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.11.3447917
S. Shao, W. Rong, S. Talukder, R. Jia, Z. Chen
{"title":"Adagrasib. GTPase KRAS (G12C mutant) inhibitor, Treatment of non-small cell lung cancer, Treatment of colorectal cancer","authors":"S. Shao, W. Rong, S. Talukder, R. Jia, Z. Chen","doi":"10.1358/dof.2022.47.11.3447917","DOIUrl":"https://doi.org/10.1358/dof.2022.47.11.3447917","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66441193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.10.3489073
L. Fernández Bertolín
{"title":"Pipeline on the Move - October 2022","authors":"L. Fernández Bertolín","doi":"10.1358/dof.2022.47.10.3489073","DOIUrl":"https://doi.org/10.1358/dof.2022.47.10.3489073","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66441350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.2.3275932
A. Akhir, A. Dasgupta, S. Chopra
{"title":"Nirsevimab. Anti-glycoprotein F (respiratory syncytial virus) monoclonal antibody, Prevention of respiratory syncytial virus-associated illness","authors":"A. Akhir, A. Dasgupta, S. Chopra","doi":"10.1358/dof.2022.47.2.3275932","DOIUrl":"https://doi.org/10.1358/dof.2022.47.2.3275932","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.2.3400575
M. Sahu, J. H. Choe
{"title":"Zimberelimab. Anti-programmed cell death protein 1 (PD-1) monoclonal antibody, Treatment of Hodgkin lymphoma, Treatment of advanced solid tumors","authors":"M. Sahu, J. H. Choe","doi":"10.1358/dof.2022.47.2.3400575","DOIUrl":"https://doi.org/10.1358/dof.2022.47.2.3400575","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.4.3381587
S. Price, A. Al-Bahou
{"title":"Navtemadlin. MDM2-p53 interaction inhibitor, Treatment of cancer","authors":"S. Price, A. Al-Bahou","doi":"10.1358/dof.2022.47.4.3381587","DOIUrl":"https://doi.org/10.1358/dof.2022.47.4.3381587","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.4.3421335
P. Sudha
The 2021 San Antonio Breast Cancer Symposium was run as a hybrid meeting allowing its attendees to participate both in person at the Henry B. Gonzalez Convention Center, San Antonio, Texas, and virtually, taking into consideration the safety of attendees due to the ongoing COVID-19 pandemic. The symposium provided state-of-the-art information on etiology, experimental biology, diagnosis, prevention and treatment of breast cancer, as well as premalignant breast diseases.
{"title":"San Antonio Breast Cancer Symposium 2021 - 44th Annual Meeting. Virtual/San Antonio - December 7-10, 2021","authors":"P. Sudha","doi":"10.1358/dof.2022.47.4.3421335","DOIUrl":"https://doi.org/10.1358/dof.2022.47.4.3421335","url":null,"abstract":"The 2021 San Antonio Breast Cancer Symposium was run as a hybrid meeting allowing its attendees to participate both in person at the Henry B. Gonzalez Convention Center, San Antonio, Texas, and virtually, taking into consideration the safety of attendees due to the ongoing COVID-19 pandemic. The symposium provided state-of-the-art information on etiology, experimental biology, diagnosis, prevention and treatment of breast cancer, as well as premalignant breast diseases.","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.5.3369189
T. Hernández-Guerrero, B. Doger, J. Luna, I. Azinovich, V. Moreno
{"title":"Positioning of hafnium oxide nanoparticles therapy in cancer treatment","authors":"T. Hernández-Guerrero, B. Doger, J. Luna, I. Azinovich, V. Moreno","doi":"10.1358/dof.2022.47.5.3369189","DOIUrl":"https://doi.org/10.1358/dof.2022.47.5.3369189","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：